Inventor
JONES ALISON
GB25 patents
⚠️ This page may combine multiple inventors who share the name “JONES ALISON”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
MISSION THERAPEUTICS LTD
20 patentsUS9926307B2Mar 27, 2018
Compounds
MISSION THERAPEUTICS LTD14 citations92
US10392380B2Aug 27, 2019
Compounds
MISSION THERAPEUTICS LTD6 citations83
US10689345B2Jun 23, 2020
1-cyano-pyrrolidine compounds as USP30 inhibitors
MISSION THERAPEUTICS LTD4 citations81
US10343992B2Jul 9, 2019
1-cyano-pyrrolidine compounds as USP30 inhibitors
MISSION THERAPEUTICS LTD7 citations81
US11472798B2Oct 18, 2022
Compounds
MISSION THERAPEUTICS LTD1 citations72
US10774078B2Sep 15, 2020
Compounds
MISSION THERAPEUTICS LTD2 citations72
US10640498B2May 5, 2020
Compounds
MISSION THERAPEUTICS LTD6 citations71
US11390584B2Jul 19, 2022
1-cyano-pyrrolidine compounds as USP30 inhibitors
MISSION THERAPEUTICS LTD1 citations70
US11993595B2May 28, 2024
Compounds
MISSION THERAPEUTICS LTD0 citations62
US11945797B2Apr 2, 2024
1-cyano-pyrrolidine derivatives as dub inhibitors
MISSION THERAPEUTICS LTD0 citations61
US11352339B2Jun 7, 2022
1-cyano-pyrrolidine derivatives as DUB inhibitors
MISSION THERAPEUTICS LTD0 citations61
US11236092B2Feb 1, 2022
Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors
MISSION THERAPEUTICS LTD0 citations61
US11319287B2May 3, 2022
Cyanopyrrolidines as dub inhibitors for the treatment of cancer
MISSION THERAPEUTICS LTD0 citations60
US11066365B2Jul 20, 2021
1-cyano-pyrrolidine compounds as USP30 inhibitors
MISSION THERAPEUTICS LTD0 citations60
US11053198B2Jul 6, 2021
1-cyano-pyrrolidine compounds as USP30 inhibitors
MISSION THERAPEUTICS LTD0 citations60
US10683269B2Jun 16, 2020
2-cyanoisoindoline derivatives for treating cancer
MISSION THERAPEUTICS LTD1 citations60
US10669234B2Jun 2, 2020
Cyanopyrrolidines as dub inhibitors for the treatment of cancer
MISSION THERAPEUTICS LTD1 citations60
US11014912B2May 25, 2021
Cyanopyrrolidine derivatives with activity as inhibitors of USP30
MISSION THERAPEUTICS LTD0 citations51
US10654853B2May 19, 2020
Spiro-condensed pyrrolidine derivatives as deubiquitylating enzymes (DUB) inhibitors
MISSION THERAPEUTICS LTD0 citations51
US11306096B2Apr 19, 2022
4,6 dihydropyrrolo [3,4-C] pyrazole-5 (1H)-carbonitrile derivates for treating cancer
MISSION THERAPEUTICS LTD0 citations50